Here's the rub, the manufacturing contractor has identified an inconsistency with one of the processes used in specification testing which is currently being rectified. Therefore IMO it's not the deoxymab but the testing process that's at fault. As they have identified it and are rectifying it I remain quietly confident. And yes, the patents could easily again IMO be worth billions. Check out the prices being paid for much lesser products.
Here's the rub, the manufacturing contractor has identified an...
-
- There are more pages in this discussion • 57 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add PAB (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
0.7¢ |
Change
0.000(0.00%) |
Mkt cap ! $14.40M | |||
| Open | High | Low | Value | Volume |
| 0.7¢ | 0.7¢ | 0.7¢ | $11.67K | 1.667M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 2 | 1024077 | 0.7¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 0.8¢ | 1520772 | 4 |
View Market Depth
| Last trade - 14.28pm 13/09/2024 (20 minute delay) ? |
| PAB (ASX) Chart |